<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331055</url>
  </required_header>
  <id_info>
    <org_study_id>2017-TCM-01</org_study_id>
    <nct_id>NCT03331055</nct_id>
  </id_info>
  <brief_title>PENS or TENS for Pain in Pancreatic Cancer</brief_title>
  <official_title>Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and
      transcutaneous nerve stimulation (TENS) for pain relieving in patients with pancreatic
      cancer. Patients will randomly allocated into PENS group, Tens group and control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PENS and TENS have been reported with analgesic effect in patients with pain, including
      cancer pain, lower back pain, neck pain, stomachache and so on.

      Effect and mechanism of PENS on pain relieving has been widely researched. With additional
      electrical stimulation in certain frequency and intensity to conventional acupuncture, pain
      controlling effect has been largely enhanced. However, invasive operation limits its
      application and acceptability, especially on pancreatic cancer.

      TENS is an advanced technique generated from PENS, which is much more welcome for its
      noninvasive character. Further more, its analgesic effect on cancer pain has been proved by
      several multi-central, randomized, clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Anticipated">October 26, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients with pancreatic cancer pain</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant is allocated randomly by staff A, and grouping situation is concealed; Technician (stuff B) or chargeing docotor operates PENS or TENS, or administers oral analgesic medication; Related datas are collected according to perdetermined forms by stuff C; Outcomes are assessed by stuff D.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>visal analogue scale (VAS) score</measure>
    <time_frame>D0-D6</time_frame>
    <description>VAS score before,during and 3 days after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantity of analgesic medication</measure>
    <time_frame>D0-D6</time_frame>
    <description>decreasing in quantity of analgesic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>times of breakthrough pain (BTP)</measure>
    <time_frame>D0-D6</time_frame>
    <description>times of BTP per day before,during and 3 days after treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>complications</measure>
    <time_frame>D1-D2</time_frame>
    <description>any correlated complications happen during or after procedure</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pain</condition>
  <condition>Cancer Pain</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>percutaneous stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trancutaneous stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional analgesic medication is offered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PENS</intervention_name>
    <description>percutaneous electrical nerve stimulation</description>
    <arm_group_label>percutaneous stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS</intervention_name>
    <description>transcutaneous electrical nerve stimulation</description>
    <arm_group_label>trancutaneous stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pancreatic cancer with pain;

          -  Haven't underwent neurolytic celiac plexus block in the past 1 month;

          -  With anticipatory survival of more than 3 months.

        Exclusion Criteria:

          -  Metastatic pancreatic cancer;

          -  Can not tolerate 30 min of lieing in prostrate or side position;

          -  PS&gt;3;

          -  Who has been recruited in other clinical trial for pain releiving;

          -  Who underwent radiotherapy or local radiactive seeds implantation for pain releiving
             in the past month;

          -  Imaging diagnosed with encephalic tumor or metastasis;

          -  Who with cardiac pacemaker or metal stand;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lihua He, Dr.</last_name>
    <phone>86-20-38993912</phone>
    <email>quincyhe@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuda Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510665</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizhi Niu, Dr.</last_name>
      <phone>86-20-38993996</phone>
      <email>niuboshi@fudahospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006276. doi: 10.1002/14651858.CD006276.pub3. Review.</citation>
    <PMID>22419313</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015 Jun 29;(6):CD009389. doi: 10.1002/14651858.CD009389.pub3. Review.</citation>
    <PMID>26121600</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen H, Liu TY, Kuai L, Zhu J, Wu CJ, Liu LM. Electroacupuncture treatment for pancreatic cancer pain: a randomized controlled trial. Pancreatology. 2013 Nov-Dec;13(6):594-7. doi: 10.1016/j.pan.2013.10.007. Epub 2013 Oct 23.</citation>
    <PMID>24280575</PMID>
  </results_reference>
  <results_reference>
    <citation>Paley CA, Johnson MI, Tashani OA, Bagnall AM. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015 Oct 15;(10):CD007753. doi: 10.1002/14651858.CD007753.pub3. Review.</citation>
    <PMID>26468973</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>percutaneous electrical nerve stimulation</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>pain</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

